Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Clinical trials for stem cell therapies

Trounson A., Thakar RG., Lomax G., Gibbons D.

Clinical Trial on Neuroinflammation, published in BMC Med (2011) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
BMC Med (2011)
Reported sample size
—
Source database
Europe PMC
PMID
21569277
PMCID
PMC3098796
DOI
10.1186/1741-7015-9-52
Citations
279

Abstract (original English)

In recent years, clinical trials with stem cells have taken the emerging field in many new directions. While numerous teams continue to refine and expand the role of bone marrow and cord blood stem cells for their vanguard uses in blood and immune disorders, many others are looking to expand the uses of the various types of stem cells found in bone marrow and cord blood, in particular mesenchymal stem cells, to uses beyond those that could be corrected by replacing cells in their own lineage. Early results from these trials have produced mixed results often showing minor or transitory improvements that may be attributed to extracellular factors. More research teams are accelerating the use of other types of adult stem cells, in particular neural stem cells for diseases where beneficial outcome could result from either in-lineage cell replacement or extracellular factors. At the same time, the first three trials using cells derived from pluripotent cells have begun.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Pluripotent Stem CellsHumansGastrointestinal DiseasesNeurodegenerative DiseasesHeart DiseasesHematologic DiseasesImmune System DiseasesTreatment OutcomeStem Cell TransplantationClinical Trials as Topic

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research